Gatik is a startup developing technology for autonomous light & medium duty trucks for B2B short-haul logistics. It specializes in the fields of artificial intelligence, automotive, and logistics. It was founded in 2017 and headquartered in Mountain View, California.
Horizon3.ai develops NodeZero which provides an autonomous penetration testing solution that helps customers find and fix attack vectors. NodeZero, Horizon3.ai's automated penetration testing solution, enables continuous security posture assessments across external, identity, on-premises, IoT, and cloud attack surfaces. Using APTs, ransomware, and other threat actors as models, the solution efficiently identifies potential vulnerabilities, misconfigurations, harvested credentials, and risky product defaults. NodeZero stands out as a true self-service SaaS offering, safe for production use without persistent or credentialed agents, giving enterprises an attacker's perspective on their security landscape.
Anello Photonics is a technology company developing a silicon photonic optical gyroscope to navigate, position, and motion track autonomous applications in challenging GPS-jammed and spoofed environments. The company's technology portfolio spans over 28 issued patents, and over 44 pending patents, and includes an AI-based sensor fusion engine. It serves the robotics, defense, construction, agriculture, and autonomous vehicles industries.
ClearBlade is the industry-leading IoT platform and Edge AI software company that enables enterprises to rapidly engineer and run secure, real-time, scalable IoT applications. Headquartered in Austin, Texas, ClearBlade is an award-winning, fully scalable, secure, flexible, and autonomous IoT cloud and Edge platform that enables companies to ingest, analyze, adapt, and act on any data in real-time and at extreme scale.
Developer of a Web-based enterprise platform designed to empower life scientists with time and cost saving software for their high-quality product development workflow. The company's platform offers scientific and technological support to streamline workflow in areas as diverse as customer needs in agricultural biotechnology and helps scientists spend more time on answering biological questions, enabling biologists to efficiently manage, quickly analyze and easily visualize microbial genome sequence data.
Umoja Biopharma is a biopharmaceutical company developing next-generation immunotherapies intended to combat cancer. The company's treatment approach retools a patient’s immune system in vivo to direct potent anti-cancer immune cells to a patient’s tumor, augmenting the body’s natural mechanisms for fighting cancer.
Rhea Space Activity (RSA) is an astrophysics start-up company in the science and technology industry. Specifically, RSA ideates and creates high-risk/high-reward R&D concepts to support U.S. national security objectives. RSA has developed various technologies in the fields of infrared satellites, directed energy, artificial intelligence, LIDAR, astroparticle physics, small satellites, cislunar operations, intelligence collection, autonomous underwater vehicles, and the F35 Lightning II.
Monitoring the quality of lifesaving medicines is Novilytic’s mission. We accomplish this via the disruptive use of nanotechnology and cutting-edge science designed for Process R&D and pharmaceutical manufacturing. The Proteometer (Proteoform Meter) is a technology for drug development companies that can provide near-real-time warnings on molecular structure changes. Like a canary in an old coal mine, the Proteometer serves as our “Canary in the Fermentor.” This technology is sold in the form of kits that allow customers to convert their LCs into a Proteometer in a short period of time. Training and service all remain the same, including one’s own software, thus ensuring ease of use and speed of adoption.
FiberX is a bio-industrial chemical company that produces renewable, sustainable, and safe bio-industrial resins made with lignin extracted from corn stover. The company was founded in 2021 and is based in Hammond, Indiana.
On Target Laboratories discovers and develops targeted intraoperative molecular imaging agents to illuminate cancer during surgery so cancerous tissue can be removed more completely. To date, there has been no reliable way for surgeons to assess the location and full extent of cancerous tissue while operating. Our molecular imaging technology, based on the pioneering work of Philip S. Low, PhD, Purdue University's Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry, aims to reduce the uncertainty associated with finding and removing cancerous tissue during surgical procedures, helping surgeons to provide a more precise and complete surgical resection.